Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 118

Therapies Virus DNA Clinical Trials 118

Broad Institute

JANUARY 30, 2024

He majored in biological chemistry at the University of Chicago and during his junior year, he had a fortuitous meeting with his academic advisor about finding a student research position that would let him dive more deeply into the molecular details of biological systems.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? in Current Biology. There’s a TV show where a bunch of doctors are walking through a hospital corridor. ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” From McKyton et al.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? in Current Biology. There’s a TV show where a bunch of doctors are walking through a hospital corridor. ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” From McKyton et al.

Therapies 52

Therapies RNA DNA Engineering 52

Drug Discovery World

NOVEMBER 9, 2023

Thereafter, there will be two presentations, which are: Jan Terje Andersen, PhD, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital, on: ‘Biology-based engineering of versatile antibody and albumin technologies’.

Engineering 130

Engineering Therapies Protein Production Science 130

Drug Target Review

JUNE 11, 2024

When choosing my bachelor’s degree, the choice was between pursuing a career in biology or in computer science. Biology won that battle, and I pursued a bachelor’s and master’s degree in biochemistry and molecular biology.

Engineering 64

Engineering Science Doctors Molecular Biology 64